HopeStage
Back to overview

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Topics
More filters
27277studies shown
Showing 7,429-7,440 of 27,277
Drug study icon
TerminatedNCT01307800

LY2140023 in people with Schizophrenia

What is this study about?

Researchers are comparing LY2140023 and placebo to find out how the approaches affect psychotic symptoms in people with schizophrenia.

This study ended early.

Multiple locations, including Wichita
SchizophreniaMedication studyAges 18–65
Countries
United States, Mexico, Russia, + 1 other
Sponsor
Denovo Biopharma LLC
Drug study icon
CompletedNCT01052103

LY2140023 in Schizophrenia people with Prominent Negative Symptoms

Official study title

A 17-Week, Phase 2, Multicenter, Randomized, Double-Blind Study of Treatment With LY2140023 Combined With Standard of Care (SOC) Compared to Placebo With SOC in the Treatment of Patients With Prominent Negative Symptoms of Schizophrenia

This study has finished and is no longer accepting participants.

Multiple locations, including Garden Grove
SchizophreniaMedication studyAges 18–65
Countries
United States, Israel, Italy, + 1 other
Sponsor
Denovo Biopharma LLC
Drug study icon
CompletedNCT01383967

LY2979165 in Healthy Subjects

Official study title

Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Multiple-Ascending Doses of LY2979165 in Healthy Subjects

This study has finished and is no longer accepting participants.

In Singapore
BipolarityMedication studyAges 21–65
Countries
Singapore
Sponsor
Eli Lilly and Company
Drug study icon
TerminatedNCT00637494

Mifepristone for depression

What is this study about?

This study evaluates the safety and effectiveness of mifepristone for people with depression.

This study ended early.

Multiple locations, including Little Rock
Depression, SchizophreniaMedication studyAges 22+
Countries
United States
Sponsor
Corcept Therapeutics
Drug study icon
CompletedNCT05953740

MK-5720 in people with Schizophrenia (MK-5720-001)

What is this study about?

This study evaluated the safety of MK-5720 for people with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Glendale
SchizophreniaMedication studyAges 18–60
Countries
United States
Sponsor
Merck Sharp & Dohme LLC
Drug study icon
WithdrawnNCT04964843

NAC for AUD

Official study title

A Pilot Study of N-acetylcysteine for Alcohol Use Disorder

This study was withdrawn before enrollment.

Location not clearly listed
AddictionMedication studyAges 18–74
Countries
Sponsor
Uniformed Services University of the Health Sciences
Drug study icon
CompletedNCT01174355

ND0801 in Attention Deficit/Hyperactivity Disorder (ADHD)

What is this study about?

This study evaluated the safety and effectiveness of ND0801 for people with ADHD.

This study has finished and is no longer accepting participants.

Multiple locations, including Haifa
ADHDMedication studyAges 18–55
Countries
Israel
Sponsor
NeuroDerm Ltd.
Device study icon
CompletedNCT04106739

New Treatment for Addiction

Official study title

Auricular Percutaneous Electrical Neural Field Stimulation in Short-Term Treatment of Alcohol Dependence- Neurohaemodynamic Correlates and Feasibility Study

This study has finished and is no longer accepting participants.

In Bengaluru
AddictionDevice studyAges 18–50
Countries
India
Sponsor
DyAnsys, Inc.
Drug study icon
CompletedNCT00970281

Olanzapine in people with Schizophrenia

What is this study about?

Researchers compared Rapid-Acting Intramuscular Olanzapine and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Aichi
SchizophreniaMedication studyAges 20–64
Countries
Japan
Sponsor
Eli Lilly and Company

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.